Skye Historical Income Statement
| SKYE Stock | USD 2.85 0.01 0.35% |
Historical analysis of Skye Bioscience, income statement accounts such as Total Revenue of 0.0, Research Development of 3.1 M, Total Operating Expenses of 8.6 M or Reconciled Depreciation of 130.5 K can show how well Skye Bioscience, Common performed in making a profits. Evaluating Skye Bioscience, income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Skye Bioscience,'s future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Skye Bioscience, Common latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Skye Bioscience, Common is a good buy for the upcoming year.
Skye |
About Skye Income Statement Analysis
Skye Bioscience, Common Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Skye Bioscience, shareholders. The income statement also shows Skye investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Skye Bioscience, Income Statement Chart
Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Net Income Applicable To Common Shares
The net income that remains after preferred dividends have been deducted, available to common shareholders.Total Revenue
Total revenue comprises all receipts Skye Bioscience, Common generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most accounts from Skye Bioscience,'s income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Skye Bioscience, Common current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At present, Skye Bioscience,'s Interest Income is projected to increase significantly based on the last few years of reporting.
| 2021 | 2022 | 2023 | 2024 (projected) | Tax Provision | 2.1K | 6.7K | 3.6K | 3.0K | Income Tax Expense | 2.1K | 6.7K | 3.6K | 2.8K |
Skye Bioscience, income statement Correlations
Click cells to compare fundamentals
Skye Bioscience, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Skye Bioscience, income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 987.8K | 706.4K | 767.5K | 665.1K | 906.3K | 567.6K | |
| Net Income Applicable To Common Shares | (19.2M) | 1.1M | (6.6M) | (8.5M) | (7.7M) | (8.1M) | |
| Net Interest Income | (1.0M) | (706.4K) | (769.2K) | (766.4K) | (806.3K) | (846.6K) | |
| Selling General Administrative | 4.4M | 4.3M | 4.9M | 6.1M | 7.9M | 5.6M | |
| Operating Income | (6.6M) | (6.3M) | (7.8M) | (18.3M) | (13.7M) | (14.4M) | |
| Net Income From Continuing Ops | 1.1M | (6.6M) | (8.5M) | (19.5M) | (37.6M) | (35.8M) | |
| Ebit | (6.6M) | (6.3M) | (7.8M) | (12.2M) | (13.7M) | (13.0M) | |
| Research Development | 2.2M | 1.9M | 2.9M | 6.0M | 5.8M | 3.1M | |
| Ebitda | 2.0M | (6.3M) | (7.8M) | (12.1M) | (13.5M) | (14.2M) | |
| Total Operating Expenses | 6.6M | 6.3M | 7.8M | 12.1M | 13.5M | 8.6M | |
| Reconciled Depreciation | 1.5K | 1.9K | 34.1K | 115.0K | 124.3K | 130.5K | |
| Income Before Tax | 1.1M | (6.6M) | (8.5M) | (19.5M) | (37.6M) | (35.8M) | |
| Total Other Income Expense Net | 8.7M | (270.1K) | (672.4K) | (7.4M) | (24.0M) | (22.8M) | |
| Net Income | 1.1M | (6.6M) | (8.5M) | (19.5M) | (37.6M) | (35.8M) | |
| Interest Income | 26.0 | 29.0 | 3.0 | 19.0K | 100.0K | 105.0K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.